Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis

Autor: Jørgen Bjerggaard Jensen, Frederik Prip, Emil Christensen, Michael Knudsen, Philippe Lamy, Trine Line Hauge Okholm, Ann Taber, Torben Steiniche, Jakob Skou Pedersen, Sia Viborg Lindskrog, Karin Birkenkamp-Demtröder, Iver Nordentoft, Lars Dyrskjøt, Mads Agerbæk

Publikováno v: Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Taber, A, Christensen, E, Lamy, P, Nordentoft, I, Prip, F, Lindskrog, S V, Birkenkamp-Demtröder, K, Okholm, T L H, Knudsen, M, Pedersen, J S, Steiniche, T, Agerbæk, M, Jensen, J B & Dyrskjøt, L 2020, ' Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis ', Nature Communications, vol. 11, no. 1, 4858 . https://doi.org/10.1038/s41467-020-18640-0
Nature Communications

Overtreatment with cisplatin-based chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for predicting response have been implemented in the clinic. Here we perform a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0e20639cc94a449f5e3e64f4f24a1c8
https://doaj.org/article/3885a19d3a524eca9c7327f222740721

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma

Autor: Ting Lu, Li Qiao, Ye Yang, Ye Hu, Wang Wang, Mengjie Guo, Rui Li, Anja Seckinger, Fenghuang Zhan, Dirk Hose, Rongfang Wei, Miaomiao Shao, Chunyan Gu

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20. CAS Article Google Scholar Palumbo A, Chanan-Khan A, Weisel K,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43f1d396323e359453dbfdfee2d99497
https://hdl.handle.net/20.500.14017/4caed97a-4e5f-44c8-9940-e891ed37fe26

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Autor: Mauro Delorenzi, Sherko Kümmel, Peter Vuylsteke, Debora Fumagalli, Christos Sotiriou, Suzan Vrijaldenhoven, Suzette Delaloge, Konstantinos Tryfonidis, Sylvian Causeret, Etienne Brain, Laura J. van't Veer, Emiel J. Th. Rutgers, Gabriele Zoppoli, Jan Bogaerts, Bart Meulemans, Jean-Yves Pierga, Fatima Cardoso, Florentine Hilbers, Aleksandra Peric, Peter M. Ravdin, Josephine M.N. Lopes Cardozo, Tineke J. Smilde, Annuska M. Glas, Giuseppe Viale, Susan J. Knox, C. Poncet, Isabel T. Rubio, Peter A. Neijenhuis, Erika Matos, Martine Piccart, Khalil Zaman, Alastair M. Thompson

Publikováno v: Lancet oncology

The MINDACT trial showed excellent 5-year distant metastasis-free survival of 94·7% (95% CI 92·5-96·2) in patients with breast cancer of high clinical and low genomic risk who did not receive chemotherapy. We present long-term follow-up results to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::999f5d47cef7e8d9fab5b9cf2e62d73b
https://pubmed.ncbi.nlm.nih.gov/33721561

A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine

Autor: Philippe Delvenne, Frédéric Lambert, Nathalie Piazzon, Séverine Valmary-Degano, Elodie Hendrick, Vincent Bours, Aurélie Poncin, Jean-Luc Prétet, Christiane Mougin, Lucine Vuitton, Karin Segers, Olivier Peulen, David Guenat, Patrick Roncarati, Franck Monnien, Benjamin Koopmansch, Diane Bruyère, Pascale Hubert, Laurence de Leval, William Penny, Michael Herfs, Alizée Lebeau, Christopher P. Crum, Charles M. Quick

Publikováno v: British Journal of Cancer
British journal of cancer, vol. 118, no. 10, pp. 1302-1312

Background Primary adenocarcinoma of the anal canal is a rare and aggressive gastrointestinal disease with unclear pathogenesis. Because of its rarity, no clear clinical practice guideline has been defined and a targeted therapeutic armamentarium has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727b845e13b0a296918d858027e98dab
http://europepmc.org/articles/PMC5959925

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Autor: Torben Plesner, René J. P. Musters, Berris van Kessel, Jeroen F. van Velzen, A. Kate Sasser, Pino J. Poddighe, Marloes E.C. Broekmans, Tuna Mutis, Inger S. Nijhof, Henk M. Lokhorst, Jakub Krejcik, Richard W.J. Groen, Kris A. Frerichs, Sonja Zweegman, Niels W.C.J. van de Donk, Andries C. Bloem, Johan van Meerloo, Christopher Chiu

Publikováno v: Krejcik, J, Frerichs, K A, Nijhof, I S, van Kessel, B, van Velzen, J, Bloem, A C, Broekmans, M, Zweegman, S, van Meerloo, J, Musters, R J, Poddighe, P, Groen, R, Chiu, C, Plesner, T, Lokhorst, H M, Sasser, A K, Mutis, T & van de Donk, N W C J 2017, ' Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab ', Clinical Cancer Research, vol. 23, no. 24, pp. 7498-7511 . https://doi.org/10.1158/1078-0432.CCR-17-2027
Krejcik, J, Frerichs, K A, Nijhof, I S, van Kessel, B, van Velzen, J F, Bloem, A C, Broekmans, M E C, Zweegman, S, van Meerloo, J, Musters, R J P, Poddighe, P J, Groen, R W J, Chiu, C, Plesner, T, Lokhorst, H M, Sasser, A K, Mutis, T & van de Donk, N W C J 2017, ' Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab ', Clinical Cancer Research, vol. 23, no. 24, pp. 7498-7511 . https://doi.org/10.1158/1078-0432.CCR-17-2027
Clinical Cancer Research, 23(24), 7498-7511. American Association for Cancer Research Inc.

Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of daratumumab-mediated CD38 reduction. Experi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a411b4972ab21d4db661d3cca064dd68
https://doi.org/10.1158/1078-0432.ccr-17-2027